The purpose of this study is to compare the usual treatment of chemotherapy (gemcitabine, paclitaxel, or docetaxel) in anti-PD(L)1-resistant advanced urothelial cancer to using pembrolizumab plus sacituzumab govitecan-hziy.

Learn more about the EA8231 trial or call the Cancer Research Office at Reading Hospital 484-628-8193.